Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Xenon Pharmaceuticals Inc.XENE · Entity 2602 | EVP, Strategy & Innovation | March 11, 2024 | March 12, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Xenon Pharmaceuticals Inc.
Report date March 11, 2024 · Filed March 12, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $44.37 · Expires 2034-03-10 | Direct | 65,000 |
Reported balance
After 2024-03-11 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-03-11 · Grant · Acquired 65,000 · Balance 65,000 F1: Vesting 25% on January 1, 2025, and 75% vesting thereafter over the course of the next 3 years, in equal amounts, on the last day of each month. |
Filing footnotes · ownership attribution and instrument terms
F1: Vesting 25% on January 1, 2025, and 75% vesting thereafter over the course of the next 3 years, in equal amounts, on the last day of each month.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 15, 2018 Filed Mar 16, 2018 20:33 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | Tax withholdingCommon Shares | 1,928 | $4.63 | $8,917.00 |
DisclosureSEC source: 0001171843-18-002049 · formfoursherrington.xml · nonDerivative · entry 2 ROBIN SHERRINGTON · CIK 0001619962 · EVP Bus. & Corp. Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,892 F2 · price: Represents the closing price of the Company's common shares on March 14, 2018, which was converted to a Canadian dollar amount for purposes of net settlement calculations. Read SEC document |
| March 15, 2018 Filed Mar 16, 2018 20:33 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | Exercise / conversionCommon Shares | 3,086 | $3.77 | $11,634.22 |
DisclosureSEC source: 0001171843-18-002049 · formfoursherrington.xml · nonDerivative · entry 1 ROBIN SHERRINGTON · CIK 0001619962 · EVP Bus. & Corp. Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,820 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The exercise price was converted to U.S. dollars from $3.74 CAD using the closing rate of exchange on the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the day of exercise. Read SEC document |
| March 12, 2018 Filed Mar 13, 2018 21:43 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | GrantStock Option (Right to Buy) · Derivative | 55,000 | $0.00 Strike: $4.75 | $0.00 |
DisclosureSEC source: 0001171843-18-001915 · formfour.xml · derivative · entry 1 ROBIN SHERRINGTON · CIK 0001619962 · EVP Bus. & Corp. Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,000 Underlying: Common Shares · 55,000 shares Expires 2028-03-11 F1 · derivative.exercise_date: Vesting 25% on January 1, 2019, and 75% vesting thereafter over the course of the next 3 years, in equal amounts, on the last day of each month. Read SEC document |
| October 23, 2017 Filed Oct 24, 2017 22:46 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | GrantStock Option (Right to Buy) · Derivative | 11,000 | $0.00 Strike: $3.10 | $0.00 |
DisclosureSEC source: 0001171843-17-006257 · formfour.xml · derivative · entry 1 ROBIN SHERRINGTON · CIK 0001619962 · SVP Bus. & Corp. Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,000 Underlying: Common Shares · 11,000 shares Expires 2027-10-22 F1 · derivative.exercise_date: Vesting 25% on October 23, 2018, and 75% vesting thereafter over the course of the next 3 years, in equal amounts, on the last day of each month. Read SEC document |
| May 12, 2017 Filed May 16, 2017 20:32 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,057 | $0.00 Strike: $3.21 | $0.00 |
DisclosureSEC source: 0001171843-17-003124 · form4.xml · derivative · entry 3 ROBIN SHERRINGTON · CIK 0001619962 · SVP Bus. & Corp. Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 2,057 shares Expires 2017-05-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The exercise price was converted to U.S. dollars from $3.74 CAD using the closing rate of exchange on the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the day of exercise. F3 · derivative.exercise_date: The shares subject to the option fully vested on December 31, 2010. Read SEC document |
| May 12, 2017 Filed May 16, 2017 20:32 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | Tax withholdingCommon Shares | 1,345 | $4.18 | $5,622.10 |
DisclosureSEC source: 0001171843-17-003124 · form4.xml · nonDerivative · entry 2 ROBIN SHERRINGTON · CIK 0001619962 · SVP Bus. & Corp. Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,734 F2 · price: Represents the closing price of the Company's common shares on May 11, 2017, which was converted to a Canadian dollar amount for purposes of net settlement calculations. Read SEC document |
| May 12, 2017 Filed May 16, 2017 20:32 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | Exercise / conversionCommon Shares | 2,057 | $3.21 | $6,602.97 |
DisclosureSEC source: 0001171843-17-003124 · form4.xml · nonDerivative · entry 1 ROBIN SHERRINGTON · CIK 0001619962 · SVP Bus. & Corp. Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,079 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The exercise price was converted to U.S. dollars from $3.74 CAD using the closing rate of exchange on the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the day of exercise. Read SEC document |
| March 13, 2017 Filed Mar 14, 2017 20:27 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | GrantStock Option (Right to Buy) · Derivative | 27,500 | $0.00 Strike: $8.40 | $0.00 |
DisclosureSEC source: 0001171843-17-001508 · formfour.xml · derivative · entry 1 ROBIN SHERRINGTON · CIK 0001619962 · SVP Bus. & Corp. Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,500 Underlying: Common Shares · 27,500 shares Expires 2027-03-12 F1 · derivative.exercise_date: Vesting 25% on January 1, 2018, and 75% vesting thereafter over the course of the next 3 years, in equal amounts, on the last day of each month. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.